Claudio Festuccia
Department of Experimental Medicine
Chair of General Pathology
University of L'Aquila
Italy
Name/email consistency: high
- Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment. Festuccia, C., Gravina, G.L., Muzi, P., Millimaggi, D., Dolo, V., Vicentini, C., Ficorella, C., Ricevuto, E., Bologna, M. Prostate (2009)
- Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Festuccia, C., Gravina, G.L., D'Alessandro, A.M., Muzi, P., Millimaggi, D., Dolo, V., Ricevuto, E., Vicentini, C., Bologna, M. Endocr. Relat. Cancer (2009)
- Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Festuccia, C., Gravina, G.L., Muzi, P., Millimaggi, D., Dolo, V., Vicentini, C., Bologna, M. Prostate (2008)
- Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Festuccia, C., Gravina, G.L., D'Alessandro, A.M., Millimaggi, D., Di Rocco, C., Dolo, V., Ricevuto, E., Vicentini, C., Bologna, M. Int. J. Oncol. (2008)
- In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Festuccia, C., Gravina, G.L., Muzi, P., Pomante, R., Ventura, L., Ricevuto, E., Vicentini, C., Bologna, M. Prostate (2007)
- Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. Festuccia, C., Gravina, G.L., Muzi, P., Biordi, L., Ronchi, P., Martella, O., Vicentini, C., Bologna, M. Oncol. Rep. (2007)
- Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Festuccia, C., Gravina, G.L., Muzi, P., Pomante, R., Ventura, L., Vessella, R.L., Vicentini, C., Bologna, M. Endocr. Relat. Cancer (2007)
- Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. Festuccia, C., Gravina, G.L., Millimaggi, D., Muzi, P., Speca, S., Ricevuto, E., Vicentini, C., Bologna, M. Oncol. Rep. (2007)
